Please assess the completion status of the following clinical trial:

Trial Title: Bupivacaine in the Treatment of Postoperative Pain of Impacted Third Molar Extraction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Lower third molars impacted bilaterally requiring an osteotomy for their extraction and which are located spatially within the following positions or classes according to Pell \& Gregory (1933).~  * Position B (occlusal plane of the impacted tooth between the occlusal plane and the cervical line of the second molar).~ * Position C (tooth impacted below the cervical line of the second molar).~ * Class II (space between the second molar and the mandibular branch smaller than the distal mesial diameter of the third molar).~ * Class III (All or most of the third molar is inside the mandibular branch).~* Systemically healthy patients (ASA I-II).~Exclusion Criteria:~We exclude patients who present a history of infectious processes in the abscess area of third molars or who, for medical reasons, chronically use some type of analgesia.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 25 Years
- Healthy Volunteers: t

Study Arms:
- Bupivacaine solution (Type: EXPERIMENTAL): In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.
- Saline solution (Type: PLACEBO_COMPARATOR): In all patients, both impacted lower third molars are surgically removed in one session, beginning the extractions in the right side. Subsequently, one of the alveolus will be irrigated with 4ml of bupivacaine 0.5% with adrenaline vasoconstrictor 1: 200,000 (BUPIROP® 0.5% ROPSOHN THERAPEUTICS SAS), the contralateral alveolus will be irrigated with 4 ml of saline solution 0.9% (Baxter laboratories) prior to the placement of the suture for the closure of the surgical wound, using the aspiration to avoid the exit of the medication out of the alveolus.

Based on this trial design, predict the completion outcome and termination type (if applicable).